EUVIMEDEUVIMED entdecken
Crossref

Identification and validation of a ubiquitination-related prognostic signature correlated with MYCN status and immune microenvironment in neuroblastoma

Chunying Jiang, Xianmei Jin

Translational Pediatrics · 2026-11 · 15 (11) · 440-440

DOI: 10.21037/tp-2026-0618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Pediatrics, 2026-11. Verfasst von Chunying Jiang und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ubiquitination plays a pivotal role in regulating MYCN stability, a key determinant of neuroblastoma progression. However, the prognostic relevance of ubiquitination-related genes associated with MYCN status in neuroblastoma remains insufficiently characterized. This study aimed to develop and validate a ubiquitination-related prognostic signature associated with MYCN status and to investigate its associations with the immune microenvironment in neuroblastoma.

Methods

Three cohorts were analyzed, including GSE49711, TARGET-NBL, and E-MTAB-8248. Ubiquitination-related differentially expressed genes (UbiquRGs) were identified based on MYCN status. Univariable Cox regression was performed to identify survival-related genes, and least absolute shrinkage and selection operator (LASSO)-Cox regression was subsequently employed to construct the risk signature associated with prognosis. A nomogram was constructed by combining the risk score with clinical parameters. Functional enrichment and gene set enrichment analysis (GSEA) were performed to explore underlying mechanisms. Immune cell infiltration, Tumor Immune Dysfunction and Exclusion (TIDE)-predicted immunotherapy response, and computationally predicted drug sensitivity were also evaluated.

Results

64 UbiquRGs were obtained by intersecting differentially expressed genes (DEGs) with the ubiquitination-related genes. Then LASSO-Cox regression identified 7 UbiquRGs (TRIM74, RNF11, WSB1, OPTN, MAP1LC3A, UBE2S, and UHRF1). Interestingly, higher risk scores were associated with poorer overall survival, higher estimated neutrophil infiltration, positive enrichment of the HALLMARK_E2F_TARGETS gene set, and negative enrichment of the HALLMARK_KRAS_SIGNALING_DN gene set in the high-risk group. External validation demonstrated varying predictive performance across cohorts, and multivariable analysis identified the risk score as an independent prognostic factor. The nomogram model showed predictive performance for overall survival, with the area under the receiver operating characteristic (ROC) curve values of 0.85, 0.89, and 0.90 for predicting 1-, 2-, and 3-year survival rates, respectively. In silico drug sensitivity analysis showed that the predicted half-maximal inhibitory concentration (IC50) values of ZM447439_1050 and Oxaliplatin_1089 exhibited the strongest positive and negative correlations with the risk score, respectively.

Conclusions

Our novel ubiquitination-related signature serves as a potential prognostic predictor and provides insights into the immune microenvironment and computationally predicted drug sensitivity in neuroblastoma.

Zitieren

APA

Jiang, C., & Jin, X. (2026). Identification and validation of a ubiquitination-related prognostic signature correlated with MYCN status and immune microenvironment in neuroblastoma. Translational Pediatrics, 15(11), 440-440. https://doi.org/10.21037/tp-2026-0618

Vancouver

Jiang C, Jin X. Identification and validation of a ubiquitination-related prognostic signature correlated with MYCN status and immune microenvironment in neuroblastoma. Translational Pediatrics. 2026;15(11):440-440. doi:10.21037/tp-2026-0618

BibTeX
@article{Jiang2026,
  author = {Jiang, Chunying and Jin, Xianmei},
  title = {Identification and validation of a ubiquitination-related prognostic signature correlated with MYCN status and immune microenvironment in neuroblastoma},
  journal = {Translational Pediatrics},
  year = {2026},
  volume = {15},
  number = {11},
  pages = {440--440},
  doi = {10.21037/tp-2026-0618}
}
Kostenlos starten →